Bone demineralisation is common in low birthweight preterm infants, with a reported incidence of up to 32%. Vitamin D metabolites are prescribed in the management and prophylaxis of early onset hypocalcaemia and rickets.1 2 There is little information available on the absorption and acute metabolic effect after oral administration of these metabolites to preterm infants. We report on 10 low birthweight preterm infants who received an equivalent oral dose of la,25-dihydroxycholecalciferol (Rocaltrol, Roche Products, Herts, United Kingdom) or la-hydroxycholecalciferol (One-Alpha, Leo Laboratories, Bucks, UK).
Patients and methods
Two groups of five infants (two boys and three girls each) were studied. Group 1, who had a median gestational age of 28 weeks (range 27-29 weeks) and birth weight of 1210 g (range 840-1360 g), received 0-1 tg/kg of One-Alpha at a median postnatal age of 4 weeks (range [3] [4] [5] . Group cresolphthalene compleximetric method with an intra-assay coefficient of variation of 2% and plasma inorganic phosphate concentration by a manual molybdate reduction method with an intra-assay coefficient of variation of 4%. Statistical analysis of all biochemical variables was performed using the Mann-Witney U test. The study was approved by the hospital ethical committee, and informed consent was obtained.
Results
The median and range of the predose plasma la,25-dihydroxycholecalciferol concentration and the median incremental increase above this basal concentration at six and 24 hours are shown in the Table. There was no significant difference between the predose concentrations of the two groups. In group 1 there was a sequential increase in plasma la,25-dihydroxycholecalciferol concentrations over the 24 hours, but this increase was not significant. In group 2, however, there was a significant increase at six hours (p<OO1), which returned towards the predose concentration at 24 hours ( Figure) . Two infants in group 1 showed a net negative change in 25-hydroxycholecalciferol, whereas three infants in group 2 showed a similar change. At 24 hours all infants in group 1 and two in group 2 showed a net positive change. The changes were not significant, however, at either time.
There was no significant change in plasma calcium or inorganic phosphate concentration in either group at six or 24 hours. pound cholecalciferol or ergocalciferol, in that they may not require in vivo hydroxylation within the liver and kidney for activation. This may be important in the preterm infant where a maturational delay in the renal enzyme la hydroxylase pathway has been implicated5 as one of the factors associated with the complex condition of rickets of prematurity. As the metabolites have an enhanced biological activity with a shorter half life compared with the parent compounds, the dose-response relation may be more easily controlled. The routine use of these agents in the prophylaxis or management of rickets of prematurity is, however, disputed.6
This study shows, for the first time, that I.a,25-dihydroxycholecalciferol (Rocaltrol) is adequately absorbed after oral administration and has a similar kinetic profile to that observed in adults.3 The precise timing of the peak concentration is uncertain as frequent blood sampling was not considered ethically justifiable in these infants. The 
